Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ran GTPase-activating protein 1 (RANGAP1) is an enzyme that regulates the activity of the small GTPase Ran by accelerating its intrinsic GTP hydrolysis, thereby converting Ran-GTP to Ran-GDP. This activity is critical in controlling the directionality and dynamics of nucleocytoplasmic transport of proteins and RNA through the nuclear pore complex. RANGAP1 acts as the functional antagonist of RCC1, which serves as the guanine nucleotide exchange factor for Ran. Through its interactions and localization, particularly at the nuclear envelope (after post-translational modification by SUMO), RANGAP1 ensures the proper shuttling of cargo molecules between the nucleus and cytoplasm. Defects in RANGAP1 function can lead to impairment of nucleocytoplasmic transport, impacting processes such as cell cycle progression and gene expression, and have been associated with some human diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ran GTPase-activating protein 1 (RANGAP1).